Author:
Eisen T,Ahmad T,Flaherty K T,Gore M,Kaye S,Marais R,Gibbens I,Hackett S,James M,Schuchter L M,Nathanson K L,Xia C,Simantov R,Schwartz B,Poulin-Costello M,O'Dwyer P J,Ratain M J
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Adnane L, Trail PA, Wilhelm S (2005) Sorafenib (BAY 43-9006) antagonizes Raf function not only by inhibiting Raf kinase activity but also by sequestering Raf protein into non-functional complexes. Presented at AACR-NCI-EORTC, November 2005, Philadelphia, PA
2. Alexandrescu DT, Dutcher JP, Wiernik PH (2005) Metastatic melanoma: is biochemotherapy the future? Med Oncol 22: 101–111
3. Awada A, Hendlisz A, Gil T, Bartholomeus S, Mano M, de Valeriola D, Strumberg D, Brendel E, Haase CG, Schwartz B, Piccart M (2005) Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 92: 1855–1861
4. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A (2001) Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 19: 3622–3634
5. Britten RA, Klein K (2000) Differential impact of Raf-1 kinase activity on tumor cell resistance to paclitaxel and docetaxel. Anticancer Drugs 11: 439–443
Cited by
560 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献